News > Pfizer, BioNTech COVID-19 Vaccine 95% Effective in Final Results: Study

Pfizer, BioNTech COVID-19 Vaccine 95% Effective in Final Results: Study

Pfizer Inc and BioNTech SE today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all the study’s primary efficacy endpoints. 

Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective).